AUTL stock forecast, quote, news & analysis
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer... Show more
Why Autolus Therapeutics (AUTL) Stock Is Down -17% in the Last 30 Days
Key Takeaways
- AUTL declined roughly 17% over the trailing 30 days, falling from about $1.86 to near $1.55, unwinding a large portion of its August rally.
- The pullback reflected profit-taking and mean reversion after a sharp, earnings-driven surge rather than any single negative company event.
- Over the trailing quarter, shares are still modestly higher, having climbed to a mid-August peak near $2.54 before fading to current levels.
- Fundamentals improved in Q2 2026, with AUCATZYL revenue up 119% year over year and gross margin reaching 55%, though the company remains unprofitable.
- Near-term catalysts include third-quarter 2026 results on November 10 and longer-term CARLYSLE lupus data at ACR Convergence 2026.
- For deeper context on valuation and expectations, explore Autolus Therapeutics' Price Targets, Earnings, and Forecast on dedicated pages.
- Discover which automated strategies are active on this ticker by exploring Trending AI Robots.
Autolus Therapeutics (AUTL) Company Overview and Market Position
Autolus Therapeutics plc is a UK-headquartered, commercial-stage biopharmaceutical company that develops, manufactures, and delivers next-generation programmed T cell therapies for cancer and autoimmune diseases. Its lead product, AUCATZYL (obe-cel), is a CD19-directed chimeric antigen receptor (CAR) T cell therapy approved for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). The company also maintains a pipeline spanning lupus, multiple sclerosis, light-chain amyloidosis, and pediatric oncology indications. Investors follow AUTL for its commercial launch momentum, improving gross margins, and a broad autoimmune expansion strategy supported by manufacturing at its Nucleus facility in the United Kingdom and a growing network of more than 80 U.S. treatment centers.
Autolus Therapeutics (AUTL) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, AUTL moved from a closing price of about $1.86 to roughly $1.55, a decline of approximately 17%. The move was gradual rather than event-driven, with the steepest leg lower occurring around the middle of October. By contrast, the trailing three-month trend tells a different story. Shares began the period near $1.45 in late July, surged to an intraday peak above $2.50 in mid-August following strong second-quarter results and a financing announcement, and have since retraced to current levels. On a net basis, the stock remains modestly higher over the trailing quarter, even though it has given back the majority of its August gains.
What Drove AUTL Stock Price in the Last 30 Days
The recent 30-day decline was largely a giveback of the August rally rather than a response to a single adverse announcement. After Autolus reported second-quarter results on August 11 that beat expectations and prompted raised full-year revenue guidance, shares spiked to a multi-month high before momentum faded. In the weeks that followed, investors appeared to lock in profits and shift focus back to lingering concerns, including continued net losses, cash burn, and the company's concentration on a single commercial product in AUCATZYL. Institutional positioning also softened, with hedge fund ownership declining and short interest near 5% of float. Management had additionally cautioned that quarterly revenue could show seasonal variability, which likely contributed to a more cautious tone heading into the next earnings report.
What Drove AUTL Stock Performance Over the Last Quarter
The broader quarterly narrative centered on a sharp re-rating higher followed by a partial unwind. On August 3, the company announced preliminary second-quarter net product revenue and a five-year, interest-only credit facility of up to $250 million with Perceptive Advisors, news that triggered an unusually heavy trading session. A week later, second-quarter results showed AUCATZYL revenue of $45.7 million, up 119% year over year, and a gross margin of 55%, up from 6% in the first quarter. Full-year 2026 revenue guidance was raised to $140 million to $150 million. Those developments drove shares from roughly $1.45 to a peak near $2.54. Since then, the absence of new near-term catalysts, combined with persistent profitability and dilution concerns, has allowed the stock to drift back toward the lower half of its 52-week range.
Trending AI Robots
Tickeron offers hundreds of AI-powered trading bots that monitor thousands of tickers, but only the top-performing and most relevant strategies are featured in its curated Trending AI Robots section. These bots vary in strategy, timeframe, and performance metrics, ranging from short-term momentum models to longer-horizon approaches, allowing users to compare different automated methodologies side by side. The section is designed to help traders and investors quickly identify which algorithmic strategies are currently generating notable results across the market. For those interested in automated signals and data-driven trading ideas, browsing the Trending AI Robots page is a practical starting point.
AUTL Stock Forecast Drivers: What Investors Should Watch Next
Looking ahead, the most important near-term event is Autolus' third-quarter 2026 earnings report on November 10, which will clarify whether AUCATZYL revenue momentum continued and whether gross margins kept improving toward the company's 65% to 70% target. Later in the year, longer-term follow-up data from the CARLYSLE trial in systemic lupus erythematosus, presented at ACR Convergence 2026, could shape sentiment around the autoimmune pipeline. Initial data from the AUTO8 program in light-chain amyloidosis and early BOBCAT results in progressive multiple sclerosis are also expected in the coming quarters. Investors should also monitor cash runway and financing needs, competitive dynamics in the CAR-T market, and whether the company can broaden revenue beyond its single marketed product.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
AUTL in upward trend: price may ascend as a result of having broken its lower Bollinger Band on November 05, 2026
AUTL may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 36 of 39 cases where AUTL's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where AUTL's RSI Oscillator exited the oversold zone, 24 of 30 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 80%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 6 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +4.76% 3-day Advance, the price is estimated to grow further. Considering data from situations where AUTL advanced for three days, in 224 of 261 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.
Bearish Trend Analysis
The Moving Average Convergence Divergence Histogram (MACD) for AUTL turned negative on November 02, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 37 similar instances when the indicator turned negative. In 31 of the 37 cases the stock turned lower in the days that followed. This puts the odds of success at 84%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AUTL declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
The Aroon Indicator for AUTL entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Seasonality Score of 23 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 33 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 71 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.552) is normal, around the industry mean (3.498). P/E Ratio (-1.208) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (4.228) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 80 (best 1 - 100 worst), indicating slightly worse than average price growth. AUTL’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AUTL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of cancer treatments
Industry Biotechnology